Skip to main content
Top
Published in: International Journal of Hematology 3/2012

01-03-2012 | Progress in Hematology

Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes

Authors: Hideki Tsushima, Masako Iwanaga, Yasushi Miyazaki

Published in: International Journal of Hematology | Issue 3/2012

Login to get access

Abstract

Leukemia was the first malignancy linked to radiation exposure in atomic bomb survivors. Clear evidence of the dose-dependent excess risk of three major types of leukemia (acute lymphocytic leukemia, acute myeloid leukemia [AML], and chronic myeloid leukemia) was found, especially in people exposed at young ages. Such leukemia risks were at their highest in the late 1950s, and declined gradually thereafter over the past 50 years. Findings from recent risk analyses, however, suggest the persistence of AML risk even after 1990, and evidence of increased risk of myelodysplastic syndromes (MDS) due to atomic bomb radiation has recently been shown. High-risk MDS and forms involving complex chromosomal aberrations were found to be much more frequent in people exposed to higher radiation doses. These lines of epidemiological evidence suggest that the risk of radiation-induced hematological malignancies has persisted for six decades since the initial exposure.
Literature
1.
go back to reference Fo1ley JH, Borges W, Yamasaki T. Incidence of leukemia in the atomic bomb survivors of Hiroshima and Nagasaki, Japan. Am J Med. 1952;13:311–21. Fo1ley JH, Borges W, Yamasaki T. Incidence of leukemia in the atomic bomb survivors of Hiroshima and Nagasaki, Japan. Am J Med. 1952;13:311–21.
2.
go back to reference Ishimaru T, Hoshino T, Ichimaru M, Okada H, Tomiyasu T. Leukemia in atomic bomb survivors, Hiroshima and Nagasaki, 1 (October), pp. 1950–30, September 1966. Radiat Res. 1971;45(1):216–33.PubMedCrossRef Ishimaru T, Hoshino T, Ichimaru M, Okada H, Tomiyasu T. Leukemia in atomic bomb survivors, Hiroshima and Nagasaki, 1 (October), pp. 1950–30, September 1966. Radiat Res. 1971;45(1):216–33.PubMedCrossRef
3.
go back to reference Ichimaru M, Ishimaru T, Belsky JH. Incidence of leukemia in Atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950–71. Radiation dose, years after exposure, age at exposure, and type of leukemia. J Radiat Res. 1978;19:262–82.PubMedCrossRef Ichimaru M, Ishimaru T, Belsky JH. Incidence of leukemia in Atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950–71. Radiation dose, years after exposure, age at exposure, and type of leukemia. J Radiat Res. 1978;19:262–82.PubMedCrossRef
4.
go back to reference Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.PubMedCrossRef Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.PubMedCrossRef
5.
go back to reference Matsuo T, Tomonaga M, Bennett JM, Kuriyama K, Imanaka F, Kuramoto A, et al. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol. 1988;18:91–6.PubMed Matsuo T, Tomonaga M, Bennett JM, Kuriyama K, Imanaka F, Kuramoto A, et al. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol. 1988;18:91–6.PubMed
6.
go back to reference Tomonaga M, Matsuo T, Carter RL, et al. Differential effects of atomic bomb irradiation in inducing major leukemia types: analyses of open-city cases including the Life Span Study cohort based upon update diagnostic systems and the dosimetry system 1986 (DS86). RERF TR 9-91. 1993. Tomonaga M, Matsuo T, Carter RL, et al. Differential effects of atomic bomb irradiation in inducing major leukemia types: analyses of open-city cases including the Life Span Study cohort based upon update diagnostic systems and the dosimetry system 1986 (DS86). RERF TR 9-91. 1993.
7.
go back to reference Kamada N, Tanaka K, Oguma N, Mabuchi K. Cytogenetic and molecular changes in leukemia among atomic bomb survivors. J Radiat Res (Tokyo). 1991;32(Suppl 2):257–65.CrossRef Kamada N, Tanaka K, Oguma N, Mabuchi K. Cytogenetic and molecular changes in leukemia among atomic bomb survivors. J Radiat Res (Tokyo). 1991;32(Suppl 2):257–65.CrossRef
8.
go back to reference Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic-bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137:S68–97.PubMedCrossRef Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic-bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137:S68–97.PubMedCrossRef
9.
go back to reference Richardson D, Sugiyama H, Nishi N, Sakata R, Shimizu Y, Grant EJ, Soda M, Hsu WL, Suyama A, Kodama K, Kasagi F. Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950–2000. Radiat Res. 2009;172:368–82.PubMedCrossRef Richardson D, Sugiyama H, Nishi N, Sakata R, Shimizu Y, Grant EJ, Soda M, Hsu WL, Suyama A, Kodama K, Kasagi F. Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950–2000. Radiat Res. 2009;172:368–82.PubMedCrossRef
10.
go back to reference Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.PubMed Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.PubMed
11.
go back to reference Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, Amenomori T, Yamamura M, Yoshida Y, Koba T, Miyazaki Y, Matsuo T, Preston DL, Suyama A, Kodama K, Tomonaga M. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29:428–34.PubMedCrossRef Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, Amenomori T, Yamamura M, Yoshida Y, Koba T, Miyazaki Y, Matsuo T, Preston DL, Suyama A, Kodama K, Tomonaga M. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29:428–34.PubMedCrossRef
Metadata
Title
Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes
Authors
Hideki Tsushima
Masako Iwanaga
Yasushi Miyazaki
Publication date
01-03-2012
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-012-1002-4

Other articles of this Issue 3/2012

International Journal of Hematology 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine